Compare Stocks → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENYSEAMERICAN:ORMNASDAQ:PSMCVE:RYONYSEARCA:SJL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$11.10-11.9%$3.45$11.07▼$35.71$11.99M1.183,849 shs3,700 shsORMOwens Realty Mortgage$21.75$0.00$14.00▼$22.95$184.51MN/A35,502 shsN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETF$29.53$29.53$15.33▼$29.53$11.81MN/A921 shsN/ARYORio SilverC$0.05+28.6%C$0.03C$0.02▼C$0.06C$3.82M2.1453,477 shs18,000 shsSJLProShares UltraShort Russell Mi$0.00$60.25▼$91.75N/AN/AN/A164,250 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%-14.81%+4,396.20%+2,821.53%PSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00%0.00%0.00%0.00%0.00%RYORio Silver0.00%-30.00%+40.00%+40.00%+16.67%SJLProShares UltraShort Russell Mi0.00%0.00%0.00%0.00%0.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AORMOwens Realty MortgageN/AN/AN/AN/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AN/AN/AN/AN/AN/ARYORio SilverN/AN/AN/AN/AN/AN/AN/AN/ASJLProShares UltraShort Russell MiN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AORMOwens Realty MortgageN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00N/AN/AN/ARYORio SilverN/AN/AN/AN/ASJLProShares UltraShort Russell MiN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K85.63N/AN/A($16.07) per share-0.69ORMOwens Realty MortgageN/AN/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AN/AN/AN/ARYORio SilverN/AN/AC$0.00 per share30.00C($0.01) per shareN/ASJLProShares UltraShort Russell MiN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/A∞N/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)ORMOwens Realty MortgageN/AN/A0.00∞N/AN/AN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/A0.00∞N/AN/AN/AN/AN/ARYORio SilverN/A-C$0.01N/A∞N/AN/AN/A-401.21%N/ASJLProShares UltraShort Russell MiN/AN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AORMOwens Realty Mortgage$0.964.41%N/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETF$0.431.46%N/AN/AN/ARYORio SilverN/AN/AN/AN/AN/ASJLProShares UltraShort Russell MiN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36ORMOwens Realty MortgageN/AN/AN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/ARYORio SilverN/A0.070.06SJLProShares UltraShort Russell MiN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%ORMOwens Realty MortgageN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/ARYORio SilverN/ASJLProShares UltraShort Russell MiN/AInsider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%ORMOwens Realty MortgageN/APSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/ARYORio Silver30.45%SJLProShares UltraShort Russell MiN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableORMOwens Realty MortgageN/A8.48 millionN/ANot OptionablePSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/A400,000N/ANot OptionableRYORio SilverN/A84.83 millionN/ANot OptionableSJLProShares UltraShort Russell MiN/AN/AN/ANot OptionableSJL, PSM, RYO, AGE, and ORM HeadlinesSourceHeadlineJonathan M. Russellhealth.usnews.com - February 4 at 12:26 AMWhen the Price of Proshares Ultrashort Russell20 $TWM Talks, People Listenmarketwatch.com - April 21 at 1:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come2 Data Storage Device Stocks Thriving From the AI BoomApril 2, 2024 7:25 AMView 2 Data Storage Device Stocks Thriving From the AI BoomMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage DemandYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Owens Realty MortgageNYSEAMERICAN:ORMOwens Realty Mortgage, Inc., a specialty finance company, focuses on the origination, investment, and management of commercial real estate loans primarily in the Western United States. It offers customized short-term loans to small and middle-market investors and developers; and holds investments in real estate properties. Owens Financial Group, Inc. serves as the manager of Owens Realty Mortgage, Inc. The company was founded in 1983 and is based in Walnut Creek, California.Principal U.S. Small-MidCap Multi-Factor ETFNASDAQ:PSMRio SilverCVE:RYORio Silver Inc. engages in the acquisition, evaluation, and development of mineral properties in the Americas, Canada, and Peru. It explores for precious and base metal deposits. The company owns 100% interest in Niñobamba silver and gold project covering an area of 4,490 hectares located in the Department of Ayacucho, Peru. It also holds 100% interest in the Gerow Lake property, a base metal project located in northwestern Ontario, Canada; and holds 100% interest in Palpa Dorado property covering an area of 1,200 hectares located in Moro district of Santa province, Ancash, Peru. The company was formerly known as Escape Gold Inc. and changed its name to Rio Silver Inc. in October 2011. Rio Silver Inc. is based in Vancouver, Canada.ProShares UltraShort Russell MiNYSEARCA:SJLProShares UltraShort Russell MidCap Value (the Fund) seeks daily investment results that correspond to twice the inverse daily performance of the Russell MidCap Value Index. The Russell MidCap Value Index measures the performance of the mid-capitalization value sector of the United States equity market. The Index represents approximately 52% of the total market capitalization of the Russell Midcap Index. The Index is a capitalization-weighted index and consists of those companies with lower price-to-book ratios within the Russell Midcap Index. The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index. The Fund intends to concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.